little by little, you can feel the building acceptance of the platform.
Key will be income versus expenditure going forward as far as the share price is concerned but I think the story will start to get out there and the Prevent trial should really be the catalyst for a major rerate.
Ann: New Corporate Oncology Account with Icon Group, page-3
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $163.8M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.1¢ | 8.1¢ | $0 | 1 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34160 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 143462 | 7 |
View Market Depth
| Last trade - 10.04am 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.000 ( 1.11 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.0¢ | 8.0¢ | 4000 | ||
| Last updated 11.01am 07/05/2024 ? | |||||
| IPD (ASX) Chart |